Food and Drug Administration Approves Drug Produced by Pfizer to Treat Rare Blood Cancer

Food and Drug Administration Approves Drug Produced by Pfizer to Treat Rare Blood Cancer

Food and Drug Administration in the United States stated on August 17, 20017 (Thursday) that it has approved a rare medication for the treatment of rare blood cancer called Besponsa, including a warning. Besponsa has been approved for the treatment of adults facing refractory or relapsed B-cell antecedent severe lymphoblastic leukemia (B-cell precursor ALL). According to the information provided by Pfizer Inc, depending on the distinctive treatment duration, the aggregate cost of the medication will be approximately US$ 168,300, before the discount is availed to its purchasers. The price listed on the drug does not necessarily have to be the price patients need to pay. ‘Out-of-pocket’ prices differ depending on the treatment duration as well as the healthcare plans the patient chooses.

A boxed warning, which is also the severest kind of cautionary note framed by the Food and Drug Administration, will be printed on Besponsa, mentioning patients treated using this medication are at highest risk of lever damage and increased death risk if the patient consumes this medication after undergoing a stem cell transplant.

B-cell precursor ALL happens to be a fast-growing cancer. In this form of cancer, the bone marrow of the patient starts making too many B-cell lymphocytes, which is supposed to be an immature kind of a white blood cell. Besposa was permitted for use in the European Union in the beginning of 2017. Besposa is a highly targeted therapy that efficiently binds the B-cell ALL cancer cells expressing the CD22 antigen, thus restricting the boost in cancer cells. As per the National Cancer Institute, B-cell precursor ALL is predicted to affect roughly 5,970 people in the U.S. and kill roughly 1,440 people this year. To control the death rate because of different types of cancer, FDA in the United States also prolonged the use of medication known as Lynparza, which is sold by Merck & Co Inc and AstraZeneca Plc.

You may be interested

Hepatitis Vaccine Market To Propel Growth Based on Rising Demand For Growing Consumer Preferences In Pharma | CMI Research
Business
Business

Hepatitis Vaccine Market To Propel Growth Based on Rising Demand For Growing Consumer Preferences In Pharma | CMI Research

Albert R - October 19, 2018

The Hepatitis Vaccine Market is expected to have a highly positive outlook for the next five years 2018 – 2026 according to a recently released Hepatitis Vaccine…

Increasing Awareness Of Home-Based Treatments Is A Prominent Factor To Fuel The Remote Patient Monitoring Devices Market
Healthcare
Healthcare

Increasing Awareness Of Home-Based Treatments Is A Prominent Factor To Fuel The Remote Patient Monitoring Devices Market

Mohit Joshi - October 19, 2018

The Remote Patient Monitoring Devices Market is expected to have a highly positive growth outlook from 2018-2025 according to a recently released Remote Patient Monitoring Devices Market research…

Tuberculosis Vaccine Market To Propel Growth Based on Rising Demand For Growing Consumer Preferences In Pharma | CMI Research
Business
Business

Tuberculosis Vaccine Market To Propel Growth Based on Rising Demand For Growing Consumer Preferences In Pharma | CMI Research

Albert R - October 19, 2018

The Tuberculosis Vaccine Market is expected to have a highly positive outlook for the next five years 2018 – 2026 according to a recently released Tuberculosis Vaccine…

Most from this category